QED Therapeutics Email Format
BiotechnologyCalifornia, United States11-50 Employees
QED Therapeutics is a biotechnology research company focused on developing treatment options for achondroplasia and advancing research into the condition's underlying biology. It is evaluating an investigational drug, infigratinib, with the aim of reducing overactivity of the FGFR3 receptor that leads to irregular bone growth. The firm operates from Palo Alto, California, as an affiliate of BridgeBio Pharma, placing it within a wider biopharma research ecosystem. In 2024, QED Therapeutics helped launch MyAchonJourney, an online platform to support individuals and families affected by achondroplasia. This initiative reflects ongoing activity in the space beyond its core research program.